Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TNFSF11 | O14788 | 3/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28436678 | 0.89 | PTGDR2 (0.48) | HTR6LMNAHTR2AHTR7PTGDR2 | |
| SCHEMBL1468385 | 0.84 | AKR1C3 (0.60) | HTR6LMNASMN1; SMN2HTR2AHTR7 | |
| SCHEMBL28436683 | 0.83 | PTGDR2 (0.47) | HTR6LMNAHTR2AHTR7PTGDR2 | |
| SCHEMBL27883477 | 0.78 | HTR6 (0.53) | HTR6LMNASMN1; SMN2PLK1MEN1 | |
| SCHEMBL3034463 | 0.77 | PPARG (0.62) | HTR6HTR2AHTR7PTGDR2PTGDR | |
| SCHEMBL28438741 | 0.76 | KDM1A (0.46) | HTR6LMNA | |
| SCHEMBL12748713 | 0.76 | HTR6 (0.54) | HTR6LMNASMN1; SMN2PTGDR2PTGDR | |
| SCHEMBL28442750 | 0.75 | PTGDR2 (0.46) | HTR6LMNAHTR2AHTR7PTGDR2 | |
| SCHEMBL12748697 | 0.75 | AKR1C3 (0.68) | HTR6LMNASMN1; SMN2PTGDR2PLK1 | |
| SCHEMBL9048832 | 0.74 | KCNH2 (0.40) | HTR6AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651637-A1 | 3-AMINO CHROMAN AND 2-AMINO TETRALIN DERIVATIVES | Wyeth (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | WYETH (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2005012291-A1 | 3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES | WYETH (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | TPH2, HTR2C, HTR7 | HTR6 8/4885LMNA 2396/4885SMN1; SMN2 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.